Medicinal Products Regulatory Support in Oman
End-to-end support from experienced Regulatory experts in Oman

Medicinal Products Regulatory Support in Oman - Overview

Oman’s pharmaceutical market is steadily growing, driven by government healthcare initiatives and increasing demand for high-quality medicinal products. Navigating the requirements of the Directorate General of Pharmaceutical Affairs and Drug Control (DGPA&DC)—including product registration, dossier submission, and Regulatory compliance—can be complex for foreign manufacturers, making Medicinal Products Regulatory Support in Oman essential for successful market entry.

Companies seeking Medicinal Product Registration in Oman must comply with local Regulatory procedures, submission requirements, and authority expectations to achieve efficient market access and ongoing compliance.

Freyr supports companies across the full Regulatory lifecycle in Oman, offering Regulatory strategy, dossier preparation, submission management, and direct coordination with DGPA&DC—helping enable compliant, efficient, and timely market access.

Medicinal Product Classification in Oman:

In Oman, the Directorate General of Pharmaceutical Affairs and Drug Control (DGPA&DC) classifies medicinal products based on therapeutic use, safety profile, prescription status, and overall risk–benefit evaluation. This classification determines the Regulatory pathway, registration requirements, prescription status (prescription or non-prescription), and pharmacovigilance obligations under national regulations—ensuring effective oversight of product approval, distribution, labeling, and post-marketing safety monitoring.

Primary Medicinal Product Categories in Oman:

1. Prescription-Only Medicines (POM):
   Medicines that require a valid prescription due to their therapeutic use, safety considerations, or the need for medical supervision.
2. Non-Prescription (OTC) Medicines:
   Products approved for supply without a prescription, evaluated for safety, quality, and suitability for self-medication.
3. Controlled Medicines:
   Medicines subject to strict control due to the potential for misuse, abuse, or dependence, requiring special prescribing, dispensing, and record-keeping procedures.
4. Narcotic and Psychotropic Substances:
   A subset of controlled medicines governed by national drug control regulations, requiring special authorization, secure handling, and detailed documentation.

Additional DGPA&DC-Regulated Product Categories:

1. Biological / Biotechnological Products:
   Includes vaccines, biosimilars, and other biologics, evaluated under stringent quality, safety, and efficacy requirements.
2. Herbal Medicinal Products:
   Herbal-based products with therapeutic claims assessed for quality, safety, and supporting evidence.
3. Traditional Herbal Medicinal Products:
   Products registered based on established traditional use and safety data, subject to Regulatory review.
4. Combination Products:
   Products containing multiple active substances or drug–device combinations, where the primary mode of action is medicinal, regulated under DGPA&DC pathways.

Medicinal Products Registration & Approval Process in Oman:

DGPA&DC, under the Ministry of Health (MOH), oversees the end-to-end Regulatory process for medicinal products in Oman, including submission review, approval, and lifecycle management. Companies must comply with DGPA&DC Regulatory Requirements in Oman, including GMP standards, pharmacovigilance obligations, and local market expectations.

Key Steps:

1. Product Classification / Pre-Submission Strategy:
   Applicants typically seek Regulatory guidance to determine product classification (conventional, biological, herbal, or combination) and the appropriate registration pathway.
2. Local Agent Requirement:
   Foreign manufacturers must appoint a local authorized agent in Oman to manage submissions, authority communication, and post-approval responsibilities.
3. Dossier Submission:
   Submission of a complete dossier (CTD/eCTD format, as applicable and accepted by DGPA&DC) covering quality, safety, and efficacy, along with supporting documents such as GMP certificates, CPP, and stability data.
4. DGPA&DC Review & Evaluation:
   DGPA&DC conducts a technical and scientific assessment of the dossier and may raise queries or request additional information during the review process.
5. Approval & Marketing Authorization (MA):
   Upon successful evaluation, DGPA&DC grants Marketing Authorization, allowing the product to be marketed in Oman. Securing market authorization for medicinal products in Oman requires successful Regulatory review, compliance verification, and fulfillment of applicable authority requirements.
6. Renewal of Authorization:
   Marketing authorizations must be renewed in accordance with Regulatory timelines, supported by updated safety, quality, and administrative data.
7. Variations / Post-Approval Changes:
   Changes to product details either administrative (manufacturer name/address) or technical (formulation, manufacturing site, labeling) require prior approval through variation submissions.
8. Post-Approval Obligations:
   MAHs must maintain pharmacovigilance systems, ensure ongoing GMP compliance, and report safety issues, quality defects, or recalls in line with local regulations in Oman.

Specific Requirements & Timelines (Indicative):

1. Registration of Conventional Medicines (PoM or OTC):
   Review timelines vary depending on dossier completeness, product type, and query resolution.
2. Renewal of Marketing Authorization:
   Renewals are generally processed within defined timelines, subject to submission of updated documentation.
3. Biological and Biotechnological Products:
   Require more extensive evaluation due to additional quality and clinical data requirements.
4. Variation / Post-Approval Changes:
   Processing timelines depend on the type of variation (minor vs. major) and the supporting data provided.
5. GMP Compliance & Manufacturer Evaluation:
   GMP certification and manufacturing site compliance are assessed during review; inspections may be required, as applicable.
6. Pricing & Market Access Considerations:
   Approved products may be subject to national pricing controls and market access requirements prior to commercialization.
7. Pharmacovigilance & Post-Market Requirements:
   Continuous safety monitoring, adverse event reporting, and compliance with post-marketing obligations are mandatory.